temozolomide has been researched along with Metastase in 76 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment using hypofractionated stereotactic radiotherapy concurrent with temozolomide appeared to be safe and could significantly extend overall survival compared with historical control in complex brain metastases." | 9.30 | A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases. ( Bi, N; Chen, X; Deng, L; Hu, C; Huang, X; Li, J; Li, Y; Liu, F; Liu, Q; Ma, Y; Tian, Y; Wang, K; Wang, W; Xiao, J; Xu, Y; Yang, S; Yi, J; Zhang, H; Zhang, Y; Zhao, R, 2019) |
| " This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer." | 9.27 | Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. ( Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML, 2018) |
| "In this multicenter, double-blind trial, adults with unresectable stage III or IV metastatic melanoma were randomized 1:1:1 to TMZ plus veliparib 20 or 40 mg, or placebo twice daily." | 9.20 | Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. ( Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M, 2015) |
| "Temozolomide (TMZ) is widely used for chemotherapy of metastatic melanoma." | 9.17 | Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. ( Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA, 2013) |
| "Patients with mucosal melanoma in stage II/III after surgery were randomized into three groups: observation group (group A, surgery alone), HDI group (group B, treated with 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 × 10(6) U IFN-α2b), and temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2)) group (group C)." | 9.17 | Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. ( Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B, 2013) |
| "The combination of oblimersen, temozolomide, and nab-paclitaxel was well tolerated and demonstrated encouraging activity in patients with advanced melanoma." | 9.17 | Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. ( Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y, 2013) |
| "In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some." | 9.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 9.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| "No responses to temozolomide were documented in these heavily pretreated women with extensive MBC including brain metastases." | 9.12 | Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). ( Bordeleau, L; Charpentier, D; Crump, M; Eisenhauer, E; Matthews, S; Trudeau, ME; Yelle, L, 2006) |
| "Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas." | 9.12 | Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006) |
| "Temozolomide (200 mg/m2 oral administration) was given to 12 patients with metastatic malignant melanoma." | 9.11 | Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005) |
| "Temozolomide (TMZ) is a new oral alkylating agent which has proven to be as active as dacarbazine (DTIC) in the treatment of melanoma, but with a lower toxicity." | 9.11 | Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. ( Amaducci, L; Biasco, G; Guida, M; Leoni, M; Michiara, M; Poletti, P; Ravaioli, A; Ridolfi, R; Romanini, A; Sileni, VC, 2004) |
| "One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28." | 9.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "Temozolomide in the schedule used has as good activity in chemotherapy-naive metastatic melanoma as the other most active agents currently in use." | 9.08 | Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. ( Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N, 1995) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 8.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 7.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 7.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| " Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases." | 7.77 | Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. ( Chen, R; Devito, N; Pan, E; Yu, M, 2011) |
| "Using a panel of 26 human melanoma-derived cell lines, we determined in vitro temozolomide sensitivity, O(6)-methylguanine-DNA methyltransferase (MGMT) activity, MGMT protein expression and promoter methylation status, and mismatch repair proficiency, as well as the expression profile of 38,000 genes using an oligonucleotide-based microarray platform." | 7.75 | Genomic and molecular profiling predicts response to temozolomide in melanoma. ( Ali-Osman, F; Augustine, CK; Friedman, HS; Nevins, JR; Potti, A; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA, 2009) |
| " 11 (44%) patients showed cerebral metastases prior to therapy with temozolomide." | 7.71 | [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. ( Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002) |
| "Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies." | 6.74 | A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. ( Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ, 2009) |
| "Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration." | 6.71 | A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. ( Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C, 2005) |
| "Temozolomide is an oral alkylating agent used for treating several cancers including glioblastoma and melanoma." | 6.66 | Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. ( Benelli, M; de Braud, F; Di Donato, S; Pietrantonio, F; Randon, G; Romagnoli, D, 2020) |
| "Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma." | 6.41 | New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000) |
| "The median time to disease progression was 8 weeks, and the overall survival duration was 26 weeks." | 5.36 | The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. ( Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C, 2010) |
| "Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4." | 5.35 | Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008) |
| "The diagnosis of an anaplastic oligodendroglioma (WHO grade 3) was made on pathological examination." | 5.35 | Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide. ( Chaskis, C; Michotte, A; Neyns, B; Sadones, J; Veld, PI, 2009) |
| "The treatment using hypofractionated stereotactic radiotherapy concurrent with temozolomide appeared to be safe and could significantly extend overall survival compared with historical control in complex brain metastases." | 5.30 | A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases. ( Bi, N; Chen, X; Deng, L; Hu, C; Huang, X; Li, J; Li, Y; Liu, F; Liu, Q; Ma, Y; Tian, Y; Wang, K; Wang, W; Xiao, J; Xu, Y; Yang, S; Yi, J; Zhang, H; Zhang, Y; Zhao, R, 2019) |
| " This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer." | 5.27 | Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. ( Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML, 2018) |
| "In this multicenter, double-blind trial, adults with unresectable stage III or IV metastatic melanoma were randomized 1:1:1 to TMZ plus veliparib 20 or 40 mg, or placebo twice daily." | 5.20 | Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. ( Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M, 2015) |
| "The combination of oblimersen, temozolomide, and nab-paclitaxel was well tolerated and demonstrated encouraging activity in patients with advanced melanoma." | 5.17 | Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. ( Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y, 2013) |
| "Patients with mucosal melanoma in stage II/III after surgery were randomized into three groups: observation group (group A, surgery alone), HDI group (group B, treated with 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 × 10(6) U IFN-α2b), and temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2)) group (group C)." | 5.17 | Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. ( Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B, 2013) |
| "Temozolomide (TMZ) is widely used for chemotherapy of metastatic melanoma." | 5.17 | Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. ( Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA, 2013) |
| "In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some." | 5.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 5.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| "No responses to temozolomide were documented in these heavily pretreated women with extensive MBC including brain metastases." | 5.12 | Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). ( Bordeleau, L; Charpentier, D; Crump, M; Eisenhauer, E; Matthews, S; Trudeau, ME; Yelle, L, 2006) |
| "Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas." | 5.12 | Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006) |
| "Temozolomide (200 mg/m2 oral administration) was given to 12 patients with metastatic malignant melanoma." | 5.11 | Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005) |
| "Temozolomide (TMZ) is a new oral alkylating agent which has proven to be as active as dacarbazine (DTIC) in the treatment of melanoma, but with a lower toxicity." | 5.11 | Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. ( Amaducci, L; Biasco, G; Guida, M; Leoni, M; Michiara, M; Poletti, P; Ravaioli, A; Ridolfi, R; Romanini, A; Sileni, VC, 2004) |
| "One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28." | 5.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "Temozolomide in the schedule used has as good activity in chemotherapy-naive metastatic melanoma as the other most active agents currently in use." | 5.08 | Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. ( Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N, 1995) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 4.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "Included patients (aged ≥18 years) had ≥1 prescription for ipilimumab, vemurafenib, temozolomide or dacarbazine between 1 January 2011 and 31 August 2013; diagnosis of melanoma and metastasis before first use (index date); no index drug use prior to the index date; continuous health plan enrollment for ≥6 months before and ≥3 months after index date." | 3.85 | Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. ( Barber, BL; Batty, N; Chen, YJ; Hines, DM; Ma, Q; Munakata, J; Zhao, Z, 2017) |
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 3.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| "Compared with temozolomide chemotherapy, the MEK inhibitor selumetinib extended progression-free survival by nearly 9 weeks in patients with melanoma of the eye participating in a phase II trial, making it the first effective drug for the rare disease." | 3.79 | Selumetinib shows promise in metastatic uveal melanoma. ( , 2013) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 3.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| " Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases." | 3.77 | Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. ( Chen, R; Devito, N; Pan, E; Yu, M, 2011) |
| " We investigated the effect of LB1, a small molecule inhibitor of serine/threonine protein phosphatase 2A (PP2A), on its ability to inhibit a low growth fraction and highly drug-resistant solid neuroendocrine tumor, such as metastatic pheochromocytoma (PHEO)." | 3.77 | Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. ( Bernardo, M; Chiang, J; Lonser, R; Lu, J; Martiniova, L; Pacak, K; Zhuang, Z, 2011) |
| " Pharmacologic characterization (chemosensitivity) was also done in four models using two drugs, temozolomide and fotemustine, currently used in the clinical management of uveal melanoma." | 3.76 | Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. ( Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S, 2010) |
| "Using a panel of 26 human melanoma-derived cell lines, we determined in vitro temozolomide sensitivity, O(6)-methylguanine-DNA methyltransferase (MGMT) activity, MGMT protein expression and promoter methylation status, and mismatch repair proficiency, as well as the expression profile of 38,000 genes using an oligonucleotide-based microarray platform." | 3.75 | Genomic and molecular profiling predicts response to temozolomide in melanoma. ( Ali-Osman, F; Augustine, CK; Friedman, HS; Nevins, JR; Potti, A; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA, 2009) |
| " These studies evaluated the antitumor efficacy of CEP-7055 using orthotopic models of glioblastoma and colon carcinoma in combination with temozolomide, and irinotecan and oxaliplatin, respectively, for their effects on primary and metastatic tumor burden and median survival." | 3.73 | The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. ( Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H, 2006) |
| " 11 (44%) patients showed cerebral metastases prior to therapy with temozolomide." | 3.71 | [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. ( Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002) |
| "Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies." | 2.74 | A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. ( Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ, 2009) |
| "Temozolomide is an alkylating agent which crosses the blood brain barrier and has demonstrated antitumor activity against a broad range of tumor types, including malignant glioma, melanoma, non small cell lung cancer and carcinoma of the ovary and colon." | 2.73 | Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. ( Bukowski, RM; Dreicer, R; Elson, P; Mekhail, T; Olencki, T; Roman, S; Tamaskar, I, 2008) |
| "Thalidomide 100 mg was kept stable for all cohorts." | 2.73 | A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007) |
| "Lomeguatrib was administered at dose levels of 10 to 40 mg/m2 days 1 to 5, as a single agent, and also in combination with temozolomide." | 2.72 | Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. ( Bridgewater, J; Dawson, M; Donnelly, D; Gumbrell, L; Halbert, G; Jowle, D; Lee, SM; Margison, GP; McElhinney, RS; McGrath, H; McMurry, TB; Middleton, MR; Ranson, M; Waller, S, 2006) |
| "Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration." | 2.71 | A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. ( Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C, 2005) |
| "Temozolomide is an oral alkylating agent used for treating several cancers including glioblastoma and melanoma." | 2.66 | Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. ( Benelli, M; de Braud, F; Di Donato, S; Pietrantonio, F; Randon, G; Romagnoli, D, 2020) |
| "High-grade glioma is a devastating disease that leaves the majority of its victims dead within 2 years." | 2.44 | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. ( Kleinberg, LR; Lin, SH, 2008) |
| "Brain metastases from renal cell carcinoma (RCC) cause significant morbidity and mortality." | 2.43 | Radiation therapy in the management of brain metastases from renal cell carcinoma. ( Amato, R; Doh, LS; Paulino, AC; Teh, BS, 2006) |
| "As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice." | 2.42 | [Therapy of malignant melanoma at the stage of distant metastasis]. ( Eigentler, TK; Garbe, C, 2004) |
| "Metastatic brain tumors are the most common complication of systemic cancer and affect 20-40% of all adult cancer patients." | 2.41 | Chemotherapy for the treatment of metastatic brain tumors. ( Newton, HB, 2002) |
| "Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma." | 2.41 | New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000) |
| "Trametinib has a strong anti-proliferative effect on established GB cell lines, stem cell-like cells and their differentiated progeny and while it does not enhance anti-proliferative and cell death-inducing properties of the standard treatment, i." | 1.56 | The limitations of targeting MEK signalling in Glioblastoma therapy. ( Debatin, KM; Hadzalic, A; Halatsch, ME; Karpel-Massler, G; Payer, C; Schuster, A; Selvasaravanan, KD; Siegelin, MD; Strobel, H; Westhoff, MA; Wiederspohn, N, 2020) |
| "The studies on the treatment of brain metastases from esophageal cancer by radiotherapy combined with temozolomide (TMZ) are even rarer." | 1.56 | Brain metastases from esophageal cancer: A case report. ( Cui, G; Li, N; Liu, C; Liu, M; Qie, S; Ran, Y; Sun, W; Sun, X; Tian, Y; Yang, H, 2020) |
| "Cell invasion and metastasis were measured by cell invasion assays." | 1.56 | Relationship between CYP17A1-Mediated DNA Demethylation and Proliferation, Invasion and Metastasis of Glioma Cells. ( Lv, W; Meng, L; Zhou, Y, 2020) |
| " According with the poor Performance Status (PS = 2) and to reduce the toxicity of the treatment was chosen an intermittent dosing regimen of metronomic temozolomide (75 mg/m(2)/day-one-week-on/on-week-off)." | 1.43 | Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. ( Arcella, A; Ascierto, PA; Cicala, D; De Divitiis, C; Grimaldi, AM; Iaffaioli, RV; Romano, GM; Simeone, E; Tafuto, S; Tatangelo, F; von Arx, C, 2016) |
| "Most patients with brain metastases have active extracranial disease, which limits survival unless effective systemic therapy can be administered." | 1.40 | Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases. ( Aandahl, G; Dalhaug, A; Haukland, E; Marienhagen, K; Nieder, C; Pawinski, A, 2014) |
| "Metastases represent the most common brain tumors in adults." | 1.40 | Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. ( Brem, H; Cima, M; Grossman, R; Hwang, L; Langer, R; Masi, B; Patta, Y; Scott, A; Spencer, K; Tyler, B; Upadhyay, UM; Wicks, R, 2014) |
| "Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment so far have been disappointing." | 1.39 | Effect of temozolomide in patients with metastatic bronchial carcinoids. ( Antonodimitrakis, P; Crona, J; Eriksson, B; Fanola, I; Granberg, D; Lindholm, DP; Öberg, K, 2013) |
| "The presence of subcutaneous metastases raised the suspicion for metastatic melanoma; however, pathological confirmation remained the ultimate tool to reach the final diagnosis." | 1.39 | Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass. ( Ejaz, S; Habra, MA; Henderson, SA; Shawa, H, 2013) |
| "Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas." | 1.37 | First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. ( Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR, 2011) |
| "The median time to disease progression was 8 weeks, and the overall survival duration was 26 weeks." | 1.36 | The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. ( Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C, 2010) |
| "The diagnosis of an anaplastic oligodendroglioma (WHO grade 3) was made on pathological examination." | 1.35 | Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide. ( Chaskis, C; Michotte, A; Neyns, B; Sadones, J; Veld, PI, 2009) |
| "Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4." | 1.35 | Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008) |
| "We studied 53 MG-PNETs in patients from 12 to 80 years of age (median = 54 years)." | 1.35 | Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. ( Burger, PC; Cochran, EJ; Gujrati, M; Holland, EC; Huse, JT; Jost, SC; Miller, CR; Perry, A; Qian, J; Raghavan, R; Rosenblum, MK; Scheithauer, BW; Zambrano, SC, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.63) | 18.2507 |
| 2000's | 32 (42.11) | 29.6817 |
| 2010's | 34 (44.74) | 24.3611 |
| 2020's | 8 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Pietrantonio, F | 1 |
| Randon, G | 1 |
| Romagnoli, D | 1 |
| Di Donato, S | 1 |
| Benelli, M | 1 |
| de Braud, F | 1 |
| Umphlett, M | 1 |
| Shea, S | 1 |
| Tome-Garcia, J | 1 |
| Zhang, Y | 2 |
| Hormigo, A | 1 |
| Fowkes, M | 1 |
| Tsankova, NM | 1 |
| Yong, RL | 1 |
| Tas, F | 1 |
| Erturk, K | 1 |
| Selvasaravanan, KD | 1 |
| Wiederspohn, N | 1 |
| Hadzalic, A | 1 |
| Strobel, H | 1 |
| Payer, C | 1 |
| Schuster, A | 1 |
| Karpel-Massler, G | 1 |
| Siegelin, MD | 1 |
| Halatsch, ME | 1 |
| Debatin, KM | 1 |
| Westhoff, MA | 1 |
| Qie, S | 1 |
| Ran, Y | 1 |
| Yang, H | 1 |
| Cui, G | 1 |
| Liu, M | 1 |
| Sun, X | 1 |
| Tian, Y | 2 |
| Sun, W | 1 |
| Li, N | 1 |
| Liu, C | 1 |
| Bongiovanni, A | 1 |
| Liverani, C | 1 |
| Foca, F | 1 |
| Fausti, V | 1 |
| Di Menna, G | 1 |
| Mercatali, L | 1 |
| De Vita, A | 1 |
| Riva, N | 1 |
| Calpona, S | 1 |
| Miserocchi, G | 1 |
| Spadazzi, C | 1 |
| Cocchi, C | 1 |
| Ibrahim, T | 1 |
| Meng, L | 1 |
| Lv, W | 1 |
| Zhou, Y | 1 |
| Lania, A | 1 |
| Ferraù, F | 1 |
| Rubino, M | 1 |
| Modica, R | 1 |
| Colao, A | 1 |
| Faggiano, A | 1 |
| Calegari, MA | 1 |
| Inno, A | 1 |
| Monterisi, S | 1 |
| Orlandi, A | 1 |
| Santini, D | 1 |
| Basso, M | 1 |
| Cassano, A | 1 |
| Martini, M | 1 |
| Cenci, T | 1 |
| de Pascalis, I | 1 |
| Camarda, F | 1 |
| Barbaro, B | 1 |
| Larocca, LM | 1 |
| Gori, S | 1 |
| Tonini, G | 1 |
| Barone, C | 1 |
| Pellini Ferreira, B | 1 |
| Vasquez, J | 1 |
| Carilli, A | 1 |
| Kinoshita, M | 1 |
| Yamada, A | 1 |
| Sawa, D | 1 |
| Kamimura, S | 1 |
| Miyachi, M | 1 |
| Moritake, H | 1 |
| Han, HS | 1 |
| Diéras, V | 1 |
| Robson, M | 1 |
| Palácová, M | 1 |
| Marcom, PK | 1 |
| Jager, A | 1 |
| Bondarenko, I | 1 |
| Citrin, D | 1 |
| Campone, M | 1 |
| Telli, ML | 1 |
| Domchek, SM | 1 |
| Friedlander, M | 1 |
| Kaufman, B | 1 |
| Garber, JE | 1 |
| Shparyk, Y | 1 |
| Chmielowska, E | 1 |
| Jakobsen, EH | 1 |
| Kaklamani, V | 1 |
| Gradishar, W | 1 |
| Ratajczak, CK | 1 |
| Nickner, C | 1 |
| Qin, Q | 1 |
| Qian, J | 3 |
| Shepherd, SP | 1 |
| Isakoff, SJ | 1 |
| Puhalla, S | 1 |
| Bao, Z | 1 |
| Chen, L | 1 |
| Guo, S | 1 |
| Bi, N | 1 |
| Ma, Y | 1 |
| Xiao, J | 1 |
| Zhang, H | 1 |
| Xu, Y | 1 |
| Li, J | 1 |
| Liu, Q | 1 |
| Wang, K | 1 |
| Deng, L | 1 |
| Wang, W | 1 |
| Chen, X | 1 |
| Liu, F | 1 |
| Zhao, R | 1 |
| Yang, S | 1 |
| Huang, X | 1 |
| Yi, J | 1 |
| Hu, C | 1 |
| Li, Y | 1 |
| Ejaz, S | 1 |
| Shawa, H | 1 |
| Henderson, SA | 1 |
| Habra, MA | 1 |
| Lian, B | 1 |
| Si, L | 1 |
| Cui, C | 1 |
| Chi, Z | 1 |
| Sheng, X | 1 |
| Mao, L | 1 |
| Li, S | 1 |
| Kong, Y | 1 |
| Tang, B | 1 |
| Guo, J | 1 |
| Crona, J | 1 |
| Fanola, I | 1 |
| Lindholm, DP | 1 |
| Antonodimitrakis, P | 1 |
| Öberg, K | 1 |
| Eriksson, B | 1 |
| Granberg, D | 1 |
| Saif, MW | 1 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Rodriguez, T | 1 |
| Moskwa, J | 1 |
| Borawska, MH | 1 |
| Markiewicz-Zukowska, R | 1 |
| Puscion-Jakubik, A | 1 |
| Naliwajko, SK | 1 |
| Socha, K | 1 |
| Soroczynska, J | 1 |
| Nieder, C | 1 |
| Marienhagen, K | 1 |
| Dalhaug, A | 1 |
| Aandahl, G | 1 |
| Haukland, E | 1 |
| Pawinski, A | 1 |
| Hadoux, J | 1 |
| Favier, J | 1 |
| Scoazec, JY | 1 |
| Leboulleux, S | 1 |
| Al Ghuzlan, A | 1 |
| Caramella, C | 1 |
| Déandreis, D | 1 |
| Borget, I | 1 |
| Loriot, C | 1 |
| Chougnet, C | 1 |
| Letouzé, E | 1 |
| Young, J | 1 |
| Amar, L | 1 |
| Bertherat, J | 1 |
| Libé, R | 1 |
| Dumont, F | 1 |
| Deschamps, F | 1 |
| Schlumberger, M | 1 |
| Gimenez-Roqueplo, AP | 1 |
| Baudin, E | 1 |
| Upadhyay, UM | 1 |
| Tyler, B | 1 |
| Patta, Y | 1 |
| Wicks, R | 1 |
| Spencer, K | 1 |
| Scott, A | 1 |
| Masi, B | 1 |
| Hwang, L | 1 |
| Grossman, R | 1 |
| Cima, M | 1 |
| Brem, H | 1 |
| Langer, R | 1 |
| Armstrong, JL | 1 |
| Hill, DS | 1 |
| McKee, CS | 1 |
| Hernandez-Tiedra, S | 1 |
| Lorente, M | 1 |
| Lopez-Valero, I | 1 |
| Eleni Anagnostou, M | 1 |
| Babatunde, F | 1 |
| Corazzari, M | 1 |
| Redfern, CPF | 1 |
| Velasco, G | 1 |
| Lovat, PE | 1 |
| Middleton, MR | 5 |
| Friedlander, P | 1 |
| Hamid, O | 1 |
| Daud, A | 1 |
| Plummer, R | 1 |
| Falotico, N | 1 |
| Chyla, B | 1 |
| Jiang, F | 1 |
| McKeegan, E | 1 |
| Mostafa, NM | 1 |
| Zhu, M | 1 |
| McKee, M | 1 |
| Luo, Y | 1 |
| Giranda, VL | 2 |
| McArthur, GA | 1 |
| De Divitiis, C | 1 |
| von Arx, C | 1 |
| Grimaldi, AM | 1 |
| Cicala, D | 1 |
| Tatangelo, F | 1 |
| Arcella, A | 1 |
| Romano, GM | 1 |
| Simeone, E | 1 |
| Iaffaioli, RV | 1 |
| Ascierto, PA | 1 |
| Tafuto, S | 1 |
| Ramirez, RA | 1 |
| Beyer, DT | 1 |
| Chauhan, A | 1 |
| Boudreaux, JP | 1 |
| Wang, YZ | 1 |
| Woltering, EA | 1 |
| Ma, Q | 1 |
| Chen, YJ | 1 |
| Hines, DM | 1 |
| Munakata, J | 1 |
| Batty, N | 1 |
| Barber, BL | 1 |
| Zhao, Z | 1 |
| Kushner, BH | 1 |
| Laquaglia, MP | 1 |
| Kramer, K | 1 |
| Modak, S | 1 |
| Cheung, NK | 1 |
| Tamaskar, I | 1 |
| Mekhail, T | 1 |
| Dreicer, R | 1 |
| Olencki, T | 1 |
| Roman, S | 1 |
| Elson, P | 1 |
| Bukowski, RM | 1 |
| Tarhini, AA | 2 |
| Kirkwood, JM | 2 |
| Gooding, WE | 1 |
| Moschos, S | 2 |
| Agarwala, SS | 1 |
| Augustine, CK | 2 |
| Yoo, JS | 2 |
| Potti, A | 1 |
| Yoshimoto, Y | 2 |
| Zipfel, PA | 1 |
| Friedman, HS | 2 |
| Nevins, JR | 1 |
| Ali-Osman, F | 2 |
| Tyler, DS | 2 |
| Mathieu, V | 1 |
| Pirker, C | 1 |
| Martin de Lassalle, E | 1 |
| Vernier, M | 1 |
| Mijatovic, T | 1 |
| DeNeve, N | 1 |
| Gaussin, JF | 1 |
| Dehoux, M | 1 |
| Lefranc, F | 1 |
| Berger, W | 1 |
| Kiss, R | 1 |
| Kefford, RF | 1 |
| Thomas, NP | 1 |
| Corrie, PG | 1 |
| Palmer, C | 1 |
| Abdi, E | 1 |
| Kotasek, D | 1 |
| Beith, J | 1 |
| Ranson, M | 3 |
| Mortimer, P | 1 |
| Watson, AJ | 2 |
| Margison, GP | 4 |
| Platta, CS | 1 |
| Khuntia, D | 1 |
| Mehta, MP | 1 |
| Suh, JH | 1 |
| Michotte, A | 1 |
| Chaskis, C | 1 |
| Sadones, J | 1 |
| Veld, PI | 1 |
| Neyns, B | 1 |
| Clark, JI | 1 |
| Moon, J | 1 |
| Hutchins, LF | 1 |
| Sosman, JA | 1 |
| Kast, WM | 1 |
| Da Silva, DM | 1 |
| Liu, PY | 1 |
| Thompson, JA | 1 |
| Flaherty, LE | 1 |
| Sondak, VK | 1 |
| Palma, JP | 1 |
| Wang, YC | 1 |
| Rodriguez, LE | 1 |
| Montgomery, D | 1 |
| Ellis, PA | 1 |
| Bukofzer, G | 1 |
| Niquette, A | 1 |
| Liu, X | 1 |
| Shi, Y | 1 |
| Lasko, L | 1 |
| Zhu, GD | 1 |
| Penning, TD | 1 |
| Rosenberg, SH | 1 |
| Frost, DJ | 1 |
| Donawho, CK | 1 |
| Yoon, C | 1 |
| Papadopoulos, NE | 1 |
| Camacho, LH | 1 |
| McIntyre, S | 1 |
| Alvarado, GC | 1 |
| Bedikian, AY | 1 |
| Hwu, P | 1 |
| Kim, KB | 1 |
| Némati, F | 1 |
| Sastre-Garau, X | 1 |
| Laurent, C | 1 |
| Couturier, J | 1 |
| Mariani, P | 1 |
| Desjardins, L | 1 |
| Piperno-Neumann, S | 1 |
| Lantz, O | 1 |
| Asselain, B | 1 |
| Plancher, C | 1 |
| Robert, D | 1 |
| Péguillet, I | 1 |
| Donnadieu, MH | 1 |
| Dahmani, A | 1 |
| Bessard, MA | 1 |
| Gentien, D | 1 |
| Reyes, C | 1 |
| Saule, S | 1 |
| Barillot, E | 1 |
| Roman-Roman, S | 1 |
| Decaudin, D | 1 |
| Jung, SH | 1 |
| Sohn, I | 1 |
| Olson, JA | 1 |
| Strosberg, JR | 1 |
| Fine, RL | 1 |
| Choi, J | 1 |
| Nasir, A | 1 |
| Coppola, D | 1 |
| Chen, DT | 1 |
| Helm, J | 1 |
| Kvols, L | 1 |
| Fateh, S | 1 |
| Schell, TD | 1 |
| Gingrich, R | 1 |
| Neves, RI | 1 |
| Drabick, JJ | 1 |
| Guida, M | 2 |
| Cramarossa, A | 1 |
| Fistola, E | 1 |
| Porcelli, M | 1 |
| Giudice, G | 1 |
| Lubello, K | 1 |
| Colucci, G | 1 |
| Martiniova, L | 1 |
| Lu, J | 1 |
| Chiang, J | 1 |
| Bernardo, M | 1 |
| Lonser, R | 1 |
| Zhuang, Z | 1 |
| Pacak, K | 1 |
| Park, MS | 1 |
| Patel, SR | 1 |
| Ludwig, JA | 1 |
| Trent, JC | 1 |
| Conrad, CA | 1 |
| Lazar, AJ | 1 |
| Wang, WL | 1 |
| Boonsirikamchai, P | 1 |
| Choi, H | 1 |
| Wang, X | 1 |
| Benjamin, RS | 1 |
| Araujo, DM | 1 |
| Devito, N | 1 |
| Yu, M | 1 |
| Chen, R | 1 |
| Pan, E | 1 |
| Raymond, E | 1 |
| Dreyer, C | 1 |
| Faivre, S | 1 |
| Ott, PA | 1 |
| Chang, J | 1 |
| Madden, K | 1 |
| Kannan, R | 1 |
| Muren, C | 1 |
| Escano, C | 1 |
| Cheng, X | 1 |
| Shao, Y | 1 |
| Mendoza, S | 1 |
| Gandhi, A | 1 |
| Liebes, L | 1 |
| Pavlick, AC | 1 |
| Tawbi, HA | 1 |
| Beumer, JH | 1 |
| Buch, SC | 1 |
| Egorin, MJ | 1 |
| Lin, Y | 1 |
| Christner, S | 1 |
| Park, DK | 1 |
| Ryan, CW | 1 |
| Dolan, ME | 1 |
| Vogelzang, NJ | 1 |
| Stadler, WM | 1 |
| Prignano, F | 1 |
| Coronnello, M | 1 |
| Pimpinelli, N | 1 |
| Cappugi, P | 1 |
| Mini, E | 1 |
| Giannotti, B | 1 |
| Frick, S | 1 |
| Lischner, S | 1 |
| Rosien, F | 1 |
| Haacke, TC | 1 |
| Schäfer, F | 1 |
| Christophers, E | 1 |
| Hauschild, A | 1 |
| Newton, HB | 1 |
| Danson, S | 1 |
| Lorigan, P | 1 |
| Arance, A | 1 |
| Clamp, A | 1 |
| Hodgetts, J | 1 |
| Lomax, L | 1 |
| Ashcroft, L | 1 |
| Thatcher, N | 3 |
| Harkness, KA | 1 |
| Manford, MR | 1 |
| Garbe, C | 1 |
| Eigentler, TK | 1 |
| Ridolfi, R | 1 |
| Romanini, A | 1 |
| Sileni, VC | 1 |
| Michiara, M | 1 |
| Biasco, G | 1 |
| Poletti, P | 1 |
| Amaducci, L | 1 |
| Leoni, M | 1 |
| Ravaioli, A | 1 |
| Plummer, ER | 1 |
| Jones, C | 1 |
| Olsen, A | 1 |
| Hickson, I | 1 |
| McHugh, P | 1 |
| McGown, G | 1 |
| Thorncroft, M | 1 |
| Boddy, AV | 1 |
| Calvert, AH | 2 |
| Harris, AL | 1 |
| Newell, DR | 1 |
| Curtin, NJ | 1 |
| Lewis, KD | 1 |
| Gibbs, P | 1 |
| O'Day, S | 1 |
| Richards, J | 1 |
| Weber, J | 1 |
| Anderson, C | 1 |
| Zeng, C | 1 |
| Baron, A | 1 |
| Russ, P | 1 |
| Gonzalez, R | 1 |
| Minor, DR | 1 |
| Madland, MT | 1 |
| Kashani-Sabet, M | 1 |
| Denny, SR | 1 |
| Harvey, WB | 1 |
| Wagner, LM | 1 |
| McAllister, N | 1 |
| Goldsby, RE | 1 |
| Rausen, AR | 1 |
| McNall-Knapp, RY | 1 |
| McCarville, MB | 1 |
| Albritton, K | 1 |
| Chamoun, RB | 1 |
| Alaraj, AM | 1 |
| Al Kutoubi, AO | 1 |
| Abboud, MR | 1 |
| Haddad, GF | 1 |
| Bridgewater, J | 1 |
| Lee, SM | 3 |
| Dawson, M | 1 |
| Jowle, D | 1 |
| Halbert, G | 1 |
| Waller, S | 1 |
| McGrath, H | 1 |
| Gumbrell, L | 1 |
| McElhinney, RS | 1 |
| Donnelly, D | 1 |
| McMurry, TB | 1 |
| Trudeau, ME | 1 |
| Crump, M | 1 |
| Charpentier, D | 1 |
| Yelle, L | 1 |
| Bordeleau, L | 1 |
| Matthews, S | 1 |
| Eisenhauer, E | 1 |
| Doh, LS | 1 |
| Amato, R | 1 |
| Paulino, AC | 1 |
| Teh, BS | 1 |
| Jones-Bolin, S | 1 |
| Zhao, H | 1 |
| Hunter, K | 1 |
| Klein-Szanto, A | 1 |
| Ruggeri, B | 1 |
| Gogas, H | 1 |
| Polyzos, A | 1 |
| Stavrinidis, I | 1 |
| Frangia, K | 1 |
| Tsoutsos, D | 1 |
| Panagiotou, P | 1 |
| Markopoulos, C | 1 |
| Papadopoulos, O | 1 |
| Pectasides, D | 1 |
| Mantzourani, M | 1 |
| Middleton, M | 1 |
| Vaiopoulos, G | 1 |
| Fountzilas, G | 1 |
| Laber, DA | 1 |
| Khan, MI | 1 |
| Kloecker, GH | 1 |
| Schonard, C | 1 |
| Taft, BS | 1 |
| Salvador, C | 1 |
| Brandsma, D | 1 |
| van den Bent, MJ | 1 |
| Lin, SH | 1 |
| Kleinberg, LR | 1 |
| Groves, MD | 1 |
| Katz, RL | 1 |
| Perry, A | 1 |
| Miller, CR | 1 |
| Gujrati, M | 1 |
| Scheithauer, BW | 1 |
| Zambrano, SC | 1 |
| Jost, SC | 1 |
| Raghavan, R | 1 |
| Cochran, EJ | 1 |
| Huse, JT | 1 |
| Holland, EC | 1 |
| Burger, PC | 1 |
| Rosenblum, MK | 1 |
| Bleehen, NM | 1 |
| Newlands, ES | 1 |
| Selby, P | 1 |
| Rustin, GJ | 1 |
| Brampton, M | 1 |
| Stevens, MF | 1 |
| Crowther, D | 1 |
| Hwu, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation [NCT01506609] | Phase 2 | 294 participants (Actual) | Interventional | 2012-01-23 | Completed | ||
| Fractionated Stereotactic Radiotherapy Combined With Temozolomide for Refractory Brain Metastases: A Single-arm, Single-center Phase II Trial[NCT02654106] | Phase 2 | 65 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma[NCT02023710] | Phase 2 | 182 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma[NCT00804908] | Phase 2 | 346 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Prospective Phase II Study in Patients With Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era[NCT03138642] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-07-01 | Recruiting | ||
| Phase I Trial of Weekly Docetaxel and Daily Temozolomide in Patients With Metastatic Disease[NCT00401180] | Phase 1 | 25 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer[NCT01679743] | Phase 2 | 0 participants (Actual) | Interventional | 2012-08-29 | Withdrawn | ||
| A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients With Metastatic Malignant Melanoma[NCT00104988] | Phase 2 | 64 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors[NCT03079440] | Phase 2 | 31 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients[NCT03023124] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-03-04 | Recruiting | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
EORTC QLQ-CIPN20 sensory subscale score was calculated following the standard scoring algorithm, transformed to a 0 (low quality of life) to 100 (best quality of life) scale. A positive change from baseline indicates improvement. (NCT01506609)
Timeframe: Baseline, Week 18
| Intervention | score on a scale (Mean) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 13.94 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 11.24 |
"CBR: percentage of participants who were progression-free at 18 weeks, defined as complete response (CR), partial response (PR), stable disease (SD) or non-CR/non-disease progression (PD) per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1.~CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 0 mm. PR: >= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters (SOD). PD: >= 20% increase in the SOD of target lesions, taking as reference the smallest SOD recorded since the treatment started (baseline or after) or the appearance of >=1 new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after)." (NCT01506609)
Timeframe: Week 18
| Intervention | percentage of participants (Number) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 87.0 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 90.7 |
| Group 2 Veliparib + TMZ | 73.0 |
The objective response rate, defined as percentage of participants with a confirmed CR or PR based on RECIST 1.1 criteria. CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 0 mm. PR: >= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline SODs. (NCT01506609)
Timeframe: Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for ORR was 34 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 61.3 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 77.8 |
| Group 2 Veliparib + TMZ | 28.6 |
Time to death for a given participant was defined as the number of months from the day the participant is randomized to the date of the participant's death. All events of death were included, regardless of whether the event occurs while the participant was still taking study drug, or after the participant discontinued study drug. If a participant had not died, then the data will be censored at the date when the participant was last known to be alive. (NCT01506609)
Timeframe: From Cycle 1 Day 1 until participant's death or 3 years post discontinuation (data cutoff date: 04 March 2016); maximum duration of follow up for OS was 72 months.
| Intervention | months (Median) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 25.4 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 28.3 |
| Group 2 Veliparib + TMZ | 19.1 |
PFS is defined as the number of months from the date the participant was randomized to the date of radiographic progression as determined by the central imaging center, or to the date of all cause deaths within 63 days of last tumor assessment if disease progression was not reached. (NCT01506609)
Timeframe: Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for PFS was 34 months.
| Intervention | months (Median) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 12.3 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 14.1 |
| Group 2 Veliparib + TMZ | 7.4 |
The 12-month overall survival rate was defined as the percentage of participants surviving at 12 months. The distribution of 12-month OS rate was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Per protocol, survival was to be assessed every 4 weeks or as needed after participant is registered as off-study for up to 18 months. The maximum observed follow-up at the overall survival analysis time was 21.0 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 52.6 |
| ABT-888 20 mg BID + TMZ QD | 43.5 |
| ABT-888 40 mg BID + TMZ QD | 54.1 |
The 6-month progression-free survival rate was defined as the percentage of participants without disease progression at 6 months.The distribution of 6-month progression-free survival rate, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every Cycle (28 Days) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 19.1 |
| ABT-888 20 mg BID + TMZ QD | 32.8 |
| ABT-888 40 mg BID + TMZ QD | 30.7 |
The disease control rate was defined as the percentage of participants who had at least stable disease (complete response, partial response, or stable disease) through the end of Week 8. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 48.7 |
| ABT-888 20 mg BID + TMZ QD | 62.9 |
| ABT-888 40 mg BID + TMZ QD | 59.1 |
The objective response rate was defined as the percentage of participants with a confirmed CR or PR per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by computed tomography (CT) scan: complete response (CR), disappearance of all target lesions; partial response (PR), ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every 2 cycles (8 weeks) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 7.0 |
| ABT-888 20 mg BID + TMZ QD | 10.3 |
| ABT-888 40 mg BID + TMZ QD | 9.6 |
OS was defined as the number of days from the date the participant was randomized to the date of death. All deaths were included, whether the participant was still taking or had discontinued study drug. If a participant had not died and was lost to follow-up, then data were censored at the last study visit or contact date, or date the participant was last known to be alive, whichever was later; if the participant was not lost to follow-up, then data were censored at the last study visit or contact date, whichever was later. The distribution of OS was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the OS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ groups were statistically significantly better than the Placebo + TMZ group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints. (NCT00804908)
Timeframe: Per protocol, survival follow-up information was to be obtained every 3 months for up to 18 months after the final visit for the subject. The maximum observed follow-up at the overall survival analysis time was 21.0 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th percentile | 75th percentile | |
| ABT-888 20 mg BID + TMZ QD | 204 | 327 | NA |
| ABT-888 40 mg BID + TMZ QD | 181 | 412 | NA |
| Placebo for ABT-888 BID + TMZ QD | 207 | 390 | 559 |
PFS: the number of days from the date that the participant was randomized to the date the participant experienced a confirmed event of disease progression (radiological, as determined by the central imaging center; or clinical, as determined by the investigator), or to the date of death (all causes of mortality) if disease progression was not reached. All events were included whether the participant was still taking or had discontinued study drug. Events of death were included for participants who had not experienced a confirmed event of disease progression, provided the death occurred within 8 weeks of the last available disease progression assessment. The distribution of PFS, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% confidence intervals (95% CIs) for the quartiles for the PFS distribution are provided. (NCT00804908)
Timeframe: Every Cycle (28 Days) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th Percentile | 75th Percentile | |
| ABT-888 20 mg BID + TMZ QD | 56 | 113 | 225 |
| ABT-888 40 mg BID + TMZ QD | 53 | 110 | 226 |
| Placebo for ABT-888 BID + TMZ QD | 54 | 60 | 163 |
The distribution of time to disease progression, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every Cycle (28 Days), until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th percentile | 75th percentile | |
| ABT-888 20 mg BID + TMZ QD | 56 | 113 | 225 |
| ABT-888 40 mg BID + TMZ QD | 53 | 110 | 226 |
| Placebo for ABT-888 BID + TMZ QD | 54 | 60 | 163 |
Time to neurological/brain metastases progression, defined as the number of days from the date of randomization to the date the participant experienced an event of neurological/brain metastases progression, was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the distribution are provided. All events of progression were included, regardless of whether the event occurred while the participant was still taking study drug. If a participant did not experience an event, data were censored at the date of the last available brain CT scan. For participants with no postbaseline brain CT scans, data were censored at randomization. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ groups were statistically significantly better than the Placebo + TMZ group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every 2 cycles (8 weeks) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th percentile | 75th percentile | |
| ABT-888 20 mg BID + TMZ QD | 119 | NA | NA |
| ABT-888 40 mg BID + TMZ QD | 184 | 184 | NA |
| Placebo for ABT-888 BID + TMZ QD | 60 | NA | NA |
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
9 reviews available for temozolomide and Metastase
| Article | Year |
|---|---|
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mis | 2020 |
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mis | 2020 |
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mis | 2020 |
Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mis | 2020 |
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neo | 2021 |
Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Cognition; Dacarbazine; Humans; Neoplasm Metastasis; Pr | 2010 |
Chemotherapy for the treatment of metastatic brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carboplatin; Clinical Trials as Topic; Dacarbazine; Humans; | 2002 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Radiation therapy in the management of brain metastases from renal cell carcinoma.
Topics: Brain Neoplasms; Carcinoma, Renal Cell; Dacarbazine; Humans; Kidney Neoplasms; Metalloporphyrins; Ne | 2006 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival | 2007 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2000 |
23 trials available for temozolomide and Metastase
| Article | Year |
|---|---|
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Breas | 2018 |
A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases.
Topics: Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Dr | 2019 |
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2013 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doce | 2008 |
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2008 |
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Child; Dacarbazine; Dose-Response Relationsh | 2009 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; | 2010 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apo | 2013 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dac | 2013 |
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinoma, Renal Cell; Dacarbazine; Drug | 2002 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
Topics: Adult; Aged; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interferon-a | 2004 |
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Dam | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2005 |
Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Child; Dacarbazine; Disease Progression; | 2006 |
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Topics: Adenosine Triphosphatases; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2007 |
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Leukopenia; Male; Melan | 1995 |
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Leu | 1994 |
44 other studies available for temozolomide and Metastase
| Article | Year |
|---|---|
Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; BRCA1 Protein; DNA Mismatch Repai | 2020 |
Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Follow-Up Studies; H | 2021 |
The limitations of targeting MEK signalling in Glioblastoma therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Adhesion; Cell Deat | 2020 |
Brain metastases from esophageal cancer: A case report.
Topics: Administration, Oral; Aftercare; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined | 2020 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Relationship between CYP17A1-Mediated DNA Demethylation and Proliferation, Invasion and Metastasis of Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dehydroepiandrosterone; DNA Demethyl | 2020 |
Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Biopsy; Capecitabine; Car | 2017 |
Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide-based combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child, Preschool; C | 2018 |
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell P | 2019 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
Selumetinib shows promise in metastatic uveal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; | 2013 |
Effect of temozolomide in patients with metastatic bronchial carcinoids.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bronchial Neoplasms; Carcinoid Tu | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |
Polish natural bee honeys are anti-proliferative and anti-metastatic agents in human glioblastoma multiforme U87MG cell line.
Topics: Animals; Antineoplastic Agents; Bees; Biological Products; Cell Line, Tumor; Cell Proliferation; Dac | 2014 |
Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.
Topics: Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; | 2014 |
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2014 |
Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capsules; | 2014 |
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; | 2015 |
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
Topics: Administration, Metronomic; Animals; Carcinoma, Neuroendocrine; Cell Differentiation; Dacarbazine; F | 2016 |
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free | 2016 |
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Databases, Factual; Female; Humans; Ind | 2017 |
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.
Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Child; Combined Modality Therapy; Dacarbazine; F | 2008 |
Genomic and molecular profiling predicts response to temozolomide in melanoma.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2009 |
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cardenolides; Cell Line, Tumor; Dacarbazine; | 2009 |
Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Arachnoid; Brain; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2009 |
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimid | 2009 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; | 2010 |
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gen | 2010 |
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening As | 2010 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Rela | 2010 |
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2010 |
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2011 |
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2011 |
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; D | 2011 |
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Di | 2012 |
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; D | 2002 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neopl | 2002 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial | 2004 |
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 2005 |
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineop | 2007 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazo | 2006 |
Low grade astrocytoma presenting with visual loss.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Daca | 2008 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |